Arvinas, Inc.
NASDAQ:ARVNBiotechnology
-$0.10 today
- Market cap
- $443.01M
- Beta
- 1.75
- P/E (TTM)
- -2.2
- EPS (TTM)
- -$3.46
Volume 1.09M
Average 0.89M
ARVN Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Arvinas, Inc.NASDAQ: ARVN
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue declines year over year
Q1 FY2026 revenue of $15.6M fell 91.7% year over year, behind the -79.1% change in trailing-twelve-month revenue. Sequentially, it rose 64.2% from the prior quarter. Over 3 fiscal years it compounded at +26.0% a year.
Context
- Revenue increased in 1 of the last 3 fiscal years.
What to watch
Whether revenue reaches the consensus estimate from 10 analysts of $277.49M (+5.7%) for the fiscal year ending Dec 2026, a step up from the -0.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $15.6M+64.2% QoQ
- Last fiscal yearDec 2025
- $262.6M-0.3% YoY
- LTMMar 2026
- $89.4M-79.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -91.7% | +171.0% | +262.8 pp |
| 1 year | -0.3% | +5.7% | +6.0 pp |
| 3-year CAGR | +26.0% | -38.3% | -64.3 pp |
| 5-year CAGR | -11.3% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 262.6M USD
- Year-over-year change
- -0.3%
- 4-year CAGR
- +48.8%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 262.6M | -0.3% |
| FY2024 | 2024-12-31 | 263.4M | +235.5% |
| FY2023 | 2023-12-31 | 78.5M | -40.3% |
| FY2022 | 2022-12-31 | 131.4M | +145.1% |
| FY2021 | 2021-12-31 | 53.6M | — |
Revenue vs competitors
How ARVN compares with its peers on the latest reported figures
- ARVN's LTM Mar 2026 revenue of $89.4M is the 3rd highest of the 6 companies compared; the peer median is $42.95M.
- Its year-over-year change of -79.1% is the lowest of 6, against a peer median of +20.1%.
- Over three fiscal years its annual growth of +26.0% compares with a peer median of +11.0%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Aug 2026 | $701.94M | +738.8% | +29.5% | |
| LTM Jun 2026 | $104.99M | +134.8% | -5.8% | |
| LTM Mar 2026 | $89.4M | -79.1% | +26.0% | |
| LTM Mar 2026 | $42.95M | -73.1% | — | |
| LTM Mar 2026 | $34.86M | -12.4% | +5.0% | |
| LTM Mar 2026 | $28.22M | +20.1% | +17.1% | |
| Peer median (excluding ARVN) | $42.95M | +20.1% | +11.0% | |
Competitors are the stored peer set for ARVN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 53.6M | 131.4M | 78.5M | 263.4M | 262.6M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 5.2M |
| Gross Profit | 53.6M | 131.4M | 78.5M | 263.4M | 257.4M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 98.0% |
| Research & Development | 180.4M | 315M | 379.7M | 348.2M | 282.9M |
| Selling, General & Admin | 61.6M | 79.6M | 100.3M | 165.4M | 89.4M |
| Operating Expenses | 242M | 394.6M | 480M | 513.6M | 372.3M |
| Depreciation & Amortization | 6M | 8.2M | 6.7M | 6.6M | 5.2M |
| EBITDA | (184.9M) | (253.4M) | (359.7M) | (191.7M) | (75.3M) |
| EBITDA Margin | -345.0% | -192.8% | -458.2% | -72.8% | -28.7% |
| Operating Income | (188.4M) | (263.2M) | (401.5M) | (250.2M) | (114.9M) |
| Operating Margin | -351.5% | -200.3% | -511.5% | -95.0% | -43.8% |
| Interest Income | 1.8M | 12M | 38.8M | 54.8M | 22M |
| Interest Expense | 100K | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (2.6M) | 1.6M | 35.1M | 51.9M | 34.4M |
| Income Before Tax | (191M) | (261.6M) | (366.4M) | (198.3M) | (80.5M) |
| Pre-Tax Margin | -356.3% | -199.1% | -466.8% | -75.3% | -30.7% |
| Income Tax Expense | 0 | 20.9M | 900K | 600K | 300K |
| Net Income | (191M) | (282.5M) | (367.3M) | (198.9M) | (80.8M) |
| Net Margin | -356.3% | -215.0% | -467.9% | -75.5% | -30.8% |
| EPS (Basic) | (3.82) | (5.31) | (6.62) | (2.77) | (1.28) |
| EPS (Diluted) | (3.82) | (5.31) | (6.62) | (2.77) | (1.28) |
| Weighted Avg Shares | 50M | 53.2M | 55.5M | 71.9M | 64.9M |
| Weighted Avg Shares (Diluted) | 50M | 53.2M | 55.5M | 71.9M | 64.9M |
Arvinas, Inc.
NASDAQ:ARVN
Intrinsic Alpha fair value
Locked
Current Price
$6.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.